ANDA 219401, held by Ascent Pharms Inc. Buprenorphine Hydrochloride.
As of Nov 16, 2026, ANDA 219401 (Buprenorphine Hydrochloride), held by Ascent Pharms Inc, was first approved by FDA on Dec 18, 2025, with 1 approved supplement and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Dec 18, 2025 | Original application | Approved | None posted |
| Buprenorphine HydrochlorideEQ 2MG BASE · tablet;sublingual | Buprenorphine Hydrochloride | Rx |
| Buprenorphine HydrochlorideEQ 8MG BASE · tablet;sublingual | Buprenorphine Hydrochloride | Rx |
| Aug 14, 2026 | Supplement 3REMS | Approved | None posted |
| Dec 18, 2025 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters